alpha-AsaroneCAS# 2883-98-9 |
- beta-Asarone
Catalog No.:BCN5685
CAS No.:5273-86-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 2883-98-9 | SDF | Download SDF |
| PubChem ID | 636822 | Appearance | White powder |
| Formula | C12H16O3 | M.Wt | 208.25 |
| Type of Compound | Phenylpropanoids | Storage | Desiccate at -20°C |
| Synonyms | trans-Asarone; Asarum camphor; trans-Isoasarone | ||
| Solubility | DMSO : 100 mg/mL (480.19 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 1,2,4-trimethoxy-5-[(E)-prop-1-enyl]benzene | ||
| SMILES | CC=CC1=CC(=C(C=C1OC)OC)OC | ||
| Standard InChIKey | RKFAZBXYICVSKP-AATRIKPKSA-N | ||
| Standard InChI | InChI=1S/C12H16O3/c1-5-6-9-7-11(14-3)12(15-4)8-10(9)13-2/h5-8H,1-4H3/b6-5+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Alpha-Asarone shows insecticidal activity. |
alpha-Asarone Dilution Calculator
alpha-Asarone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.8019 mL | 24.0096 mL | 48.0192 mL | 96.0384 mL | 120.048 mL |
| 5 mM | 0.9604 mL | 4.8019 mL | 9.6038 mL | 19.2077 mL | 24.0096 mL |
| 10 mM | 0.4802 mL | 2.401 mL | 4.8019 mL | 9.6038 mL | 12.0048 mL |
| 50 mM | 0.096 mL | 0.4802 mL | 0.9604 mL | 1.9208 mL | 2.401 mL |
| 100 mM | 0.048 mL | 0.2401 mL | 0.4802 mL | 0.9604 mL | 1.2005 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Denudanolide A
Catalog No.:BCN6522
CAS No.:288259-72-3
- Y-320
Catalog No.:BCC5202
CAS No.:288250-47-5
- Phlorigidoside B
Catalog No.:BCN5189
CAS No.:288248-46-4
- 3,4-Dihydroxyphenylglycol
Catalog No.:BCN5188
CAS No.:28822-73-3
- IBMX
Catalog No.:BCC7502
CAS No.:28822-58-4
- Z-Ala-OMe
Catalog No.:BCC3056
CAS No.:28819-05-8
- SB408124
Catalog No.:BCC4972
CAS No.:288150-92-5
- Cixiophiopogon A
Catalog No.:BCN2778
CAS No.:288143-27-1
- Fraxinellone
Catalog No.:BCN1272
CAS No.:28808-62-0
- 4,7-Bis(5-bromo-2-thienyl)-2,1,3-benzothiadiazole
Catalog No.:BCC8668
CAS No.:288071-87-4
- Heraclenin
Catalog No.:BCN5187
CAS No.:2880-49-1
- Tetrazole
Catalog No.:BCC2847
CAS No.:288-94-8
- Lithospermic acid
Catalog No.:BCN5369
CAS No.:28831-65-4
- (-)-dicentrine
Catalog No.:BCC8167
CAS No.:28832-07-7
- Cediranib (AZD217)
Catalog No.:BCC1121
CAS No.:288383-20-0
- H-Asp(OBzl)-OBzl.TosOH
Catalog No.:BCC2886
CAS No.:2886-33 -1
- S-(-)-Carbidopa
Catalog No.:BCN8453
CAS No.:28860-95-9
- Z-D-Met-OH
Catalog No.:BCC2758
CAS No.:28862-80-8
- Ergosta-5,24(28)-diene-3,7,16-triol
Catalog No.:BCN5190
CAS No.:289054-34-8
- 3,7,16-Trihydroxystigmast-5-ene
Catalog No.:BCN5191
CAS No.:289056-24-2
- Triazolam
Catalog No.:BCC5218
CAS No.:28911-01-5
- Fmoc-Cl
Catalog No.:BCC2802
CAS No.:28920-43-6
- Anodendrine
Catalog No.:BCN1956
CAS No.:28942-07-6
- Canertinib dihydrochloride
Catalog No.:BCC1449
CAS No.:289499-45-2
Corrigendum: Oral Administration of alpha-Asarone Promotes Functional Recovery in Rats With Spinal Cord Injury.[Pubmed:30202415]
Front Pharmacol. 2018 Aug 30;9:949.
[This corrects the article DOI: 10.3389/fphar.2018.00445.].
Oral Administration of alpha-Asarone Promotes Functional Recovery in Rats With Spinal Cord Injury.[Pubmed:29867457]
Front Pharmacol. 2018 May 7;9:445.
alpha-Asarone, a bioactive compound found in Acorus plant species, has been shown to exhibit neuroprotective, anti-oxidative, anti-inflammatory, and cognitive-enhancing effects. However, the effects of alpha-Asarone on spinal cord injury (SCI) have not yet been elucidated. The present study investigated the effects of alpha-Asarone on the mRNA of pro-inflammatory cytokines, macrophage polarization toward an anti-inflammatory M2 phenotype, and angiogenesis in rats with compressive SCI. alpha-Asarone was orally administered (10 mg/kg) once per day for 14 days following moderate static compression SCI. Compared to controls, alpha-Asarone treatment significantly improved locomotor score, prevented neuroinflammation, and facilitated angiogenesis in the spinal cord at 14 days after SCI. Furthermore, alpha-Asarone significantly reduced the TNF-alpha, IL-1beta, IL-6, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 2 (MIP-2), and inducible nitric oxide synthase (iNOS) levels but increased the IL-4, IL-10, and arginase 1 levels at 24 h after SCI. At 7 and 14 days after SCI, immunohistochemistry showed reduced reactive gliosis and neuroinflammation and an increased expression of M2 macrophage markers and angiogenesis. The results suggest that the inhibition of pro-inflammatory cytokines, macrophage polarization toward an anti-inflammatory M2 phenotype, and angiogenesis by alpha-Asarone may be some of the mechanisms underlying the alpha-Asarone-mediated neuroprotective effects on an injured spinal cord.
